In focus · trending topic

Tislelizumab

1 stories · following the connections

BeiGene Presents Initial Phase 1b Data for BTK Inhibitor Zanubrutinib (BGB-3111) Combined with PD-1 Antibody Tislelizumab (BGB-A317) at the 59th American Society of Hematology Annual Meeting

By Nasdaq OMXDec 11, 2017, 3:00 PM UTC